{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:18:38Z","timestamp":1778275118326,"version":"3.51.4"},"reference-count":9,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Calcium pyrophosphate dihydrate (CPPD) crystal deposition disease, clinically known as pseudogout (PG), is an acute inflammatory arthritis that may rarely occur following bisphosphonate (BP) exposure. Zoledronic acid (ZA) is widely used for osteoporosis and hypercalcemia; however, crystal-induced arthritis is an uncommon adverse event. We describe a 65-year-old woman with primary hyperparathyroidism (PHPT) presenting with persistent hypercalcemia. Initial laboratory evaluation showed calcium of 11.1\u2005mg\/dL (SI: 2.78\u2005mmol\/L) (reference range, 8.8-10.2\u2005mg\/dL [SI: 2.20-2.55\u2005mmol\/L]) and parathyroid hormone of 89.31\u2005pg\/mL (SI: 9.47\u2005pmol\/L) (reference range, 15-65\u2005pg\/mL [SI: 1.6-6.9\u2005pmol\/L]). Imaging failed to localize a parathyroid lesion. Due to uncontrolled hypercalcemia and osteoporosis, intravenous ZA was administered. Three days later, she developed nausea, diffuse musculoskeletal pain, and laboratory findings consistent with acute kidney injury, requiring hospitalization. On the third hospital day, acute pain, swelling, warmth, and restricted movement occurred in the right elbow. Septic arthritis was excluded after negative cultures. Rheumatologic evaluation confirmed PG. Corticosteroid therapy led to rapid improvement. Advanced age, PHPT, baseline hypercalcemia, and a rapid calcium decline likely contributed to the CPPD crystal flare. Clinicians should consider PG after bisphosphonate use.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag068","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:42:00Z","timestamp":1773751320000},"source":"Crossref","is-referenced-by-count":1,"title":["Pseudogout attack following zoledronic acid treatment in primary hyperparathyroidism"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-2070","authenticated-orcid":false,"given":"Yasemin","family":"Emur Gunay","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Giresun University Faculty of Medicine , Giresun 28600 ,","place":["T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmut","family":"Gunay","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Traumatology, Giresun University Faculty of Medicine , Giresun 28100 ,","place":["T\u00fcrkiye"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"2","key":"2026042204393786100_luag068-B1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.36740\/WLek\/200864","article-title":"Calcium pyrophosphate dihydrate deposition disease (chondrocalcinosis): a review","volume":"78","author":"\u017byluk","year":"2025","journal-title":"Wiad Lek"},{"issue":"2","key":"2026042204393786100_luag068-B2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/BOR.0000000000000690","article-title":"Progresses in the imaging of calcium pyrophosphate crystal disease","volume":"32","author":"Andr\u00e9s","year":"2020","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"2026042204393786100_luag068-B3","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1308\/rcsann.2018.0028","article-title":"Pseudogout - a rare manifestation of hungry bone syndrome after focused parathyroidectomy","volume":"100","author":"Tai","year":"2018","journal-title":"Ann R Coll Surg Engl"},{"issue":"2","key":"2026042204393786100_luag068-B4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jbspin.2016.11.004","article-title":"First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy","volume":"84","author":"Couture","year":"2017","journal-title":"Joint Bone Spine"},{"issue":"2","key":"2026042204393786100_luag068-B5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.5606\/tftrd.2023.10135","article-title":"A case of pseudogout attack after zoledronic acid treatment in primary hyperparathyroidism","volume":"69","author":"Co\u015fkun","year":"2022","journal-title":"Turk J Phys Med Rehabil"},{"issue":"2","key":"2026042204393786100_luag068-B6","first-page":"202","article-title":"Pseudogout attack after zoledronic acid treatment for bone metastasis from prostate cancer","volume":"15","author":"Ohara","year":"2010","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"2026042204393786100_luag068-B7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00296-018-4029-x","article-title":"Pseudogout among patients fulfilling a billing code algorithm for calcium pyrophosphate deposition disease","volume":"38","author":"Tedeschi","year":"2018","journal-title":"Rheumatol Int"},{"key":"2026042204393786100_luag068-B8","doi-asserted-by":"crossref","first-page":"1327715","DOI":"10.3389\/fmed.2024.1327715","article-title":"Recent advances in the therapeutic management of calcium pyrophosphate deposition disease","volume":"11","author":"Voulgari","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"2026042204393786100_luag068-B9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10067-018-4272-2","article-title":"Efficacy and tolerance of anakinra in acute calcium pyrophosphate crystal arthritis: a retrospective study of 33 cases","volume":"38","author":"Thomas","year":"2019","journal-title":"Clin Rheumatol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/5\/luag068\/68133745\/luag068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/5\/luag068\/68133745\/luag068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:39:43Z","timestamp":1776847183000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag068\/8660676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,21]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag068","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,21]]},"article-number":"luag068"}}